Civitas raises $38M to advance drug for Parkinson's complication

09/12/2013 | American City Business Journals

A Series B funding round has brought in $38 million for Chelsea, Mass.-based biotech firm Civitas Therapeutics. Civitas plans to use the money to support clinical development of its experimental drug CVT-301, which is under development for debilitating motor fluctuations in Parkinson's disease patients.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA